A Comparison of Efficacy of Intravenous Esomeprazole and Ranitidine Treatment of Dyspeptic Pain

Launched by PAMUKKALE UNIVERSITY · Jul 18, 2014

Keywords

ClinConnect Summary

* this is the placebo randomized double blinded clinical trial to compare the efficacy of these three drugs in this clinical setting.
* A randomized clinical trial was conducted in the ED of Pamukkale University Medical Faculty Hospital
* Study personnel (emergency physicians and nurses) were trained before the study.
* When intravenous drugs (esomeprazol, ranitidine or plasebo) was being recommended, an eligibility checklist was completed by the attending physician.
* If there were no exclusion criteria, written informed consent was obtained and baseline information, including initial disp...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • patients were eligible for inclusion if they were aged 18 years or older, 60 years or older,
• • had dyspspsia \[VAS (visual analog scale) score \>5\] during their ED episode of care for which the attending physician recommended medication.
• Exclusion Criteria:
• • pretreatment 100-mm linear visual analog scale (VAS) pain score less than 50 mm;
• • known cases of malignancy or terminal illness;
• • known cases of major medical problems (eg, any evidence of active structural or functional abnormality of the hearts, chronic renal failure)
• • allergy or previous adverse reaction to study drugs studied
• • received agents to inhibit the secretion of acid (PPIs or histamine-2 receptor antagonists), nonsteroidal anti-inflammatory drugs,
• • who consumed alcohol within 4 hours before the ED visit
• • diarrhea more than 2 times within the past 24 hours;
• • being suspected to have other ED diagnoses (eg, gut obstruction, biliary colic, pancreatitis, hepatitis, or localized hepatobiliary infections);
• • being pregnant or breast-feeding; and
• • inability to comprehend the VAS evaluation.
• • and patients who refused to participate study.